Usana Health Sciences, Inc. (USNA)
USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript
USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript
USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.73 per share a year ago.
Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USNA vs. SDZNY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks is more attractive to value investors?
USNA or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
USANA Health (USNA) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
USANA Health (USNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
USANA Health (USNA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
USANA Health (USNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
USANA Looks Like An Undervalued Turnaround Stock
USANA Health Sciences is executing a strategic pivot from its declining MLM core to high-growth brands Hiya and Rise Wellness. Hiya's Disney collaboration and subscription model drive projected 23% revenue growth, while Rise Wellness secures major retail distribution for Protein Pop. USNA trades at a significant valuation discount (EV/EBITDA 2.67), with a projected 2026 target price of $24.33—25% above current levels.
Is USANA Health Sciences (USNA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USNA or UTHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
USANA Health Sciences, Inc. (USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences, Inc. (USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.64 per share a year ago.
